Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR101 Two-dose Regimen Post-Haploidentical HSCT
NCT02500550Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 6
01
Overview
A Phase 2 trial of ATIR101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by Kiadis Pharma. Started Oct 2015; status: completed.
02
Drugs
ATIR101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02500550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500550.